These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21057903)

  • 1. Intravenous iron in heart failure: beyond targeting anemia.
    Silverberg DS; Iaina A; Schwartz D; Wexler D
    Curr Heart Fail Rep; 2011 Mar; 8(1):14-21. PubMed ID: 21057903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
    Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
    J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
    Usmanov RI; Zueva EB; Silverberg DS; Shaked M
    J Nephrol; 2008; 21(2):236-42. PubMed ID: 18446719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure.
    Zilberman M; Silverberg DS; Bits I; Steinbruch S; Wexler D; Sheps D; Schwartz D; Oksenberg A
    Am Heart J; 2007 Nov; 154(5):870-6. PubMed ID: 17967592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
    Comin-Colet J; Lainscak M; Dickstein K; Filippatos GS; Johnson P; Lüscher TF; Mori C; Willenheimer R; Ponikowski P; Anker SD
    Eur Heart J; 2013 Jan; 34(1):30-8. PubMed ID: 22297124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron.
    Toblli JE; Di Gennaro F; Rivas C
    Heart Lung Circ; 2015 Jul; 24(7):686-95. PubMed ID: 25666998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
    Anker SD; Colet JC; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Mori C; von Eisenhart Rothe B; Pocock S; Poole-Wilson PA; Ponikowski P;
    Eur J Heart Fail; 2009 Nov; 11(11):1084-91. PubMed ID: 19875408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an accelerated intravenous iron regimen in hospitalized patients with advanced heart failure and iron deficiency.
    Reed BN; Blair EA; Thudium EM; Waters SB; Sueta CA; Jensen BC; Rodgers JE
    Pharmacotherapy; 2015 Jan; 35(1):64-71. PubMed ID: 25556867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous iron therapy in heart failure: a different perspective.
    Ghafourian K; Chang HC; Ardehali H
    Eur J Heart Fail; 2019 Jun; 21(6):703-714. PubMed ID: 30884037
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.
    Silverberg DS; Wexler D; Blum M; Keren G; Sheps D; Leibovitch E; Brosh D; Laniado S; Schwartz D; Yachnin T; Shapira I; Gavish D; Baruch R; Koifman B; Kaplan C; Steinbruch S; Iaina A
    J Am Coll Cardiol; 2000 Jun; 35(7):1737-44. PubMed ID: 10841219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous Iron Use in the Care of Patients with Kidney Disease.
    Macdougall IC
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1528-1530. PubMed ID: 31175103
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
    Charles-Edwards G; Amaral N; Sleigh A; Ayis S; Catibog N; McDonagh T; Monaghan M; Amin-Youssef G; Kemp GJ; Shah AM; Okonko DO
    Circulation; 2019 May; 139(21):2386-2398. PubMed ID: 30776909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.
    Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Sanchis J; Chorro FJ; Bayés-Genís A; Núñez J;
    Clin Cardiol; 2018 Jun; 41(6):729-735. PubMed ID: 29607528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study.
    Silverberg DS; Wexler D; Sheps D; Blum M; Keren G; Baruch R; Schwartz D; Yachnin T; Steinbruch S; Shapira I; Laniado S; Iaina A
    J Am Coll Cardiol; 2001 Jun; 37(7):1775-80. PubMed ID: 11401110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral or intravenous iron for anemia correction in chronic kidney disease?
    Drüeke TB; Massy ZA
    Kidney Int; 2015 Oct; 88(4):673-5. PubMed ID: 26422625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
    Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Meta-analysis of Intravenous Iron Therapy for Patients With Iron Deficiency and Heart Failure.
    Osman M; Syed M; Balla S; Kheiri B; Faisaluddin M; Bianco C
    Am J Cardiol; 2021 Feb; 141():152-153. PubMed ID: 33259800
    [No Abstract]   [Full Text] [Related]  

  • 20. Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure.
    McCullough PA; Uhlig K; Neylan JF; Pergola PE; Fishbane S
    Am J Cardiol; 2018 Aug; 122(4):683-688. PubMed ID: 29961562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.